BA (bile acid) formation is considered an important final step in RCT (reverse cholesterol transport). HDL (high-density lipoprotein) has been reported to transport BAs. We therefore investigated the effects of monogenic disturbances in human HDL metabolism on serum concentrations and lipoprotein distributions of the major 15 BA species and their precursor C4 (7α-hydroxy-4-cholesten-3-one). In normolipidaemic plasma, approximately 84%, 11% and 5% of BAs were recovered in the LPDS (lipoprotein-depleted serum), HDL and the combined LDL (low-density lipoprotein)/VLDL (very-low-density lipoproteins) fraction respectively. Conjugated BAs were slightly over-represented in HDL. For C4, the respective percentages were 23%, 21% and 56% (41% in LDL and 15% in VLDL) respectively. Compared with unaffected family members, neither HDL-C (HDL-cholesterol)-decreasing mutations in the genes APOA1 [encoding ApoA-I (apolipoprotein A-I], ABCA1 (ATP-binding cassette transporter A1) or LCAT (lecithin:cholesterol acyltransferase) nor HDL-C-increasing mutations in the genes CETP (cholesteryl ester transfer protein) or LIPC (hepatic lipase) were associated with significantly different serum concentrations of BA and C4. Plasma concentrations of conjugated and secondary BAs differed between heterozygous carriers of SCARB1 (scavenger receptor class B1) mutations and unaffected individuals (P<0.05), but this difference was not significant after correction for multiple testing. Moreover, no differences in the lipoprotein distribution of BAs in the LPDS and HDL fractions from SCARB1 heterozygotes were observed. In conclusion, despite significant recoveries of BAs and C4 in HDL and despite the metabolic relationships between RCT and BA formation, monogenic disorders of HDL metabolism do not lead to altered serum concentrations of BAs and C4.
Skip Nav Destination
Article navigation
Research Article|
December 14 2011
Lipoprotein distribution and serum concentrations of 7α-hydroxy-4-cholesten-3-one and bile acids: effects of monogenic disturbances in high-density lipoprotein metabolism
Carine Steiner;
Carine Steiner
*Institute of Clinical Chemistry, University Hospital Zurich, CH-8091 Zurich, Switzerland
†Competence Center for Systems Physiology and Metabolic Diseases, ETH Zurich and University of Zurich, CH-8093 Zurich, Switzerland
Search for other works by this author on:
Adriaan G. Holleboom;
Adriaan G. Holleboom
‡Department of Experimental Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
Search for other works by this author on:
Ratna Karuna;
Ratna Karuna
*Institute of Clinical Chemistry, University Hospital Zurich, CH-8091 Zurich, Switzerland
†Competence Center for Systems Physiology and Metabolic Diseases, ETH Zurich and University of Zurich, CH-8093 Zurich, Switzerland
Search for other works by this author on:
Mohammad M. Motazacker;
Mohammad M. Motazacker
‡Department of Experimental Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
Search for other works by this author on:
Jan Albert Kuivenhoven;
Jan Albert Kuivenhoven
‡Department of Experimental Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
Search for other works by this author on:
Ruth Frikke-Schmidt;
Ruth Frikke-Schmidt
§Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
Search for other works by this author on:
Anne Tybjaerg-Hansen;
Anne Tybjaerg-Hansen
§Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark
Search for other works by this author on:
Lucia Rohrer;
Lucia Rohrer
1
*Institute of Clinical Chemistry, University Hospital Zurich, CH-8091 Zurich, Switzerland
¶Center for Integrative Human Physiology, University of Zurich, CH-8093 Zurich, Switzerland
Search for other works by this author on:
Katharina M. Rentsch;
Katharina M. Rentsch
1
*Institute of Clinical Chemistry, University Hospital Zurich, CH-8091 Zurich, Switzerland
¶Center for Integrative Human Physiology, University of Zurich, CH-8093 Zurich, Switzerland
Search for other works by this author on:
Arnold von Eckardstein
Arnold von Eckardstein
1
*Institute of Clinical Chemistry, University Hospital Zurich, CH-8091 Zurich, Switzerland
†Competence Center for Systems Physiology and Metabolic Diseases, ETH Zurich and University of Zurich, CH-8093 Zurich, Switzerland
¶Center for Integrative Human Physiology, University of Zurich, CH-8093 Zurich, Switzerland
Correspondence: Dr Arnold von Eckardstein (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
September 16 2011
Revision Received:
October 19 2011
Accepted:
October 20 2011
Accepted Manuscript online:
October 20 2011
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2012 Biochemical Society
2012
Clin Sci (Lond) (2012) 122 (8): 385–400.
Article history
Received:
September 16 2011
Revision Received:
October 19 2011
Accepted:
October 20 2011
Accepted Manuscript online:
October 20 2011
Citation
Carine Steiner, Adriaan G. Holleboom, Ratna Karuna, Mohammad M. Motazacker, Jan Albert Kuivenhoven, Ruth Frikke-Schmidt, Anne Tybjaerg-Hansen, Lucia Rohrer, Katharina M. Rentsch, Arnold von Eckardstein; Lipoprotein distribution and serum concentrations of 7α-hydroxy-4-cholesten-3-one and bile acids: effects of monogenic disturbances in high-density lipoprotein metabolism. Clin Sci (Lond) 1 April 2012; 122 (8): 385–400. doi: https://doi.org/10.1042/CS20110482
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.